




Highlights of Our Oncology Clinical Trial Management Experience

- Bladder
- Brain
- Breast
- Colorectal
- Head & Neck
- Immunotherapy
- Leukemias
- Lymphomas
- Lung
- Melanoma
- Multiple Myeloma
- Myelodysplasia
- Ovarian
- Pancreas
- Prostate

Providing support to 460+ programs, treating 65,000 patients, at 6,000 sites, from a database of over 11,000 investigators.





Therapeutic Area / Indication	Study Phase	Sites	Patients
AL Amyloidosis	I	20	50
B Thalassemia	II	4	46
Bladder	II	20	50
Bladder, Muscle Invasive	II	18	60
Bladder, Transitional Cell Carcinoma	I	10	45
Bladder, Transitional Cell Carcinoma	I	11	45
Bladder, Transitional Cell Carcinoma; Pancreatic (cholangiocarcinoma); Cervical; Head & Neck	II	16	160
Brain, Glioblastoma Multiforme (GBM)	II	50	168
Brain, Glioblastoma Multiforme (GBM)	II	80	140
Brain, Glioblastoma Multiforme (GBM)	III	50	760
Brain, Glioblastoma Multiforme (GBM)	III	235	700
Brain, Rhabdomyosarcoma or Medulloblastoma	I	4	55
Breast	BioEq	75	41
Breast	I	1	36
Breast	I	3	86
Breast	I/II	2	26
Breast	II	2	21
Breast	II	2	30
Breast	II	2	60
Breast	II	4	30
Breast	II	4	50
Breast	II	25	150
Breast	II	30	65
Breast	IIb	20	80
Breast	III	4	11
Breast	III	46	243
Breast	III	48	243
Breast	III	60	450
Breast; Lung, Non-Small Cell (NSCLC)	II/III	217	4,690
Breast, Reconstruction	I	1	140
Breast; Melanoma	III	22	238

Therapeutic Area / Indication	Study Phase	Sites	Patients
Breast; Melanoma	IV/Post-Marketing	20	238
Breast; Ovarian	Ib	4	42
Breast; Solid Tumors	I	5	190
Breast; Solid Tumors	I	6	50
Cervical	Pivotal	264	46,989
Colorectal	EAP	10	50
Colorectal	EAP	44	1,394
Colorectal	EAP	44	2,112
Colorectal	EAP	57	215
Colorectal	EAP	130	1,384
Colorectal	I	1	15
Colorectal	I	1	24
Colorectal	I	2	20
Colorectal	I	6	30
Colorectal	I/II	1	30
Colorectal	I/II	2	70
Colorectal	II	1	70
Colorectal	II	4	48
Colorectal	II	5	50
Colorectal	II	11	50
Colorectal	II	24	150
Colorectal	II	40	100
Colorectal	II	75	214
Colorectal	IIb	41	300
Colorectal	III	70	220
Colorectal	III	188	240
Colorectal	Pivotal	3	622
Gastric; Hepatocellular Carcinoma; Renal Cell Carcinoma	Ib/II	5	57
Gastric; Hepatocellular Carcinoma; Renal Cell Carcinoma	Ib/II	5	60
Gastrointestinal (GI) Tumors	I	2	35
Gastrointestinal Stromal Tumors (GIST)	II	8	26
Head and Neck (SCCHN)	II	10	150



Therapeutic Area / Indication	Study Phase	Sites	Patients
Head and Neck (SCCHN)	III	6	260
Head and Neck (SCCHN)	III	10	18
Head and Neck (SCCHN)	III	23	73
Head and Neck (SCCHN)	III	44	1,394
Head and Neck (SCCHN)	III	80	528
Hematologic Malignancies	I	1	30
Hematologic Malignancies	I	2	59
Hematologic Malignancies	I	10	20
Hematologic Malignancies	I	10	97
Hematologic Malignancies	I/II	12	106
Hematologic Malignancies	II	2	30
Hematologic Malignancies	III	75	230
Hematologic Malignancies or Solid Tumors	I	10	30
Hematologic Malignancies; Leukemia, Acute Myeloid; Myelodysplastic Syndrome	I	15	50
Hematologic Malignancies; Stem Cell Transplant	I	4	15
Hematologic Malignancies; Stem Cell Transplant	I	4	22
Hematologic Malignancies; Stem Cell Transplant	II	1	16
Hematologic Malignancies; Stem Cell Transplant	II	5	50
Hematologic Malignancies; Stem Cell Transplant	II	6	50
Hematologic Malignancies; Stem Cell Transplant	III	60	529
Hepatocellular Carcinoma (HCC)	I	1	12
Hepatocellular Carcinoma (HCC)	I	1	24
Hepatocellular Carcinoma (HCC)	I/II	6	50
Hepatocellular Carcinoma (HCC)	Ib/II	9	60
Hepatocellular Carcinoma (HCC)	II	6	40
Hepatocellular Carcinoma (HCC)	Pivotal	26	81
Hepatocellular Carcinoma (HCC); Non-Small Cell Lung Cancer; Melanoma	Ib	1	10
Hepatocellular Carcinoma (HCC); Non-Small Cell Lung Cancer; Melanoma	Ib	1	10
Leukemia or Lymphoma	IIb	25	100

Therapeutic Area / Indication	Study Phase	Sites	Patients
Leukemia, Acute Lymphoblastic; Non-Hodgkin Lymphoma	I/II	14	25
Leukemia, Acute Myeloid (AML)	I	4	39
Leukemia, Acute Myeloid (AML)	I/II	21	78
Leukemia, Acute Myeloid (AML)	II	8	40
Leukemia, Acute Myeloid (AML)	II	30	160
Leukemia, Acute Myeloid (AML)	II	100	325
Leukemia, Acute Myeloid (AML)	IIb	40	120
Leukemia, Acute Myeloid (AML)	III	30	480
Leukemia, Acute Myeloid (AML)	III	38	240
Leukemia, Acute Myeloid (AML)	III	88	450
Leukemia, Acute Myeloid (AML)	III	134	326
Leukemia, Acute Myeloid or Lymphocytic	I	15	35
Leukemia, Acute Myeloid or Lymphocytic; Myelodysplastic Syndrome	I/II	11	54
Leukemia, Acute Myeloid; Myelodysplastic Syndrome	I	1	27
Leukemia, Chronic Lymphocytic (CLL)	I	2	72
Leukemia, Chronic Lymphocytic (CLL)	I/Ib	5	20
Leukemia, Chronic Lymphocytic (CLL)	II	1	30
Leukemia, Chronic Lymphocytic (CLL)	II	1	33
Leukemia, Chronic Lymphocytic (CLL)	III	4	15
Leukemia, Chronic Lymphocytic (CLL)	III	15	58
Leukemia, Chronic Lymphocytic (CLL)	III	120	330
Leukemia, Chronic Lymphocytic; Lymphoma, Non-Hodgkin	I/Ib	5	60
Leukemia, Chronic Lymphocytic; Lymphoma, Non-Hodgkin	I/II	20	94
Leukemia, Chronic Lymphocytic; Lymphoma, Non-Hodgkin	Ib	5	50
Leukemia, Chronic Myelogenous (CML)	III	175	528
Leukemia, Chronic Myelogenous; Gastrointestinal Stromal Tumors	BioEq	15	42
Leukemia, Chronic Myeloid	I/II	36	60
Leukemia, Relapsed or Refractory Chronic Lymphocytic	I	10	190



Therapeutic Area / Indication	Study Phase	Sites	Patients
Leukemia, Relapsed or Refractory Chronic Lymphocytic	I/II	2	3
Leukemia, Relapsed or Refractory Chronic Lymphocytic	I/II	19	250
Liposarcoma	II	11	30
Lung, Mesothelioma	I/II	1	54
Lung, Non-Small Cell (NSCLC)	I	2	60
Lung, Non-Small Cell (NSCLC)	I	6	30
Lung, Non-Small Cell (NSCLC)	I/II	14	60
Lung, Non-Small Cell (NSCLC)	I/II	17	70
Lung, Non-Small Cell (NSCLC)	II	6	40
Lung, Non-Small Cell (NSCLC)	II	17	20
Lung, Non-Small Cell (NSCLC)	II	20	140
Lung, Non-Small Cell (NSCLC)	II	25	83
Lung, Non-Small Cell (NSCLC)	II	26	100
Lung, Non-Small Cell (NSCLC)	II	27	102
Lung, Non-Small Cell (NSCLC)	II	29	102
Lung, Non-Small Cell (NSCLC)	II	55	210
Lung, Non-Small Cell (NSCLC)	II	60	150
Lung, Non-Small Cell (NSCLC)	III	100	390
Lung, Non-Small Cell (NSCLC)	III	200	205
Lung, Non-Small Cell (NSCLC)	III	203	205
Lung, Non-Small Cell (NSCLC)	III	400	1,050
Lung, Non-Small Cell, Advanced Non-Squamous	II	25	69
Lung, Non-Small Cell, Non-Squamous	IV/Post-Marketing	135	1,800
Lung, Small Cell (SCLC)	Ib/II	5	120
Lung, Small Cell (SCLC)	III	220	900
Lymphoid Malignancies	I	4	85
Lymphoid Malignancies or Solid Tumor	I	3	47
Lymphoma	I	6	34
Lymphoma, Anaplastic Large Cell (ALCL)	II	13	40
Lymphoma, Cutaneous T-Cell (CTCL)	I	6	15
Lymphoma, Cutaneous T-Cell (CTCL)	II	41	120
Lymphoma, Follicular	I/II	30	75

Therapeutic Area / Indication	Study Phase	Sites	Patients
Lymphoma, Follicular	Ib/II	30	120
Lymphoma, Follicular	II	40	88
Lymphoma, Follicular Non-Hodgkin	II	6	50
Lymphoma, Hodgkin; Lymphoma, Systemic Anaplastic Large Cell	I/Ib	5	20
Lymphoma, Mantle Cell; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	II	20	70
Lymphoma, Non-Hodgkin (NHL)	II	10	50
Lymphoma, Non-Hodgkin (NHL)	II	15	43
Lymphoma, Non-Hodgkin (NHL)	III	40	300
Lymphoma, Non-Hodgkin (NHL)	III	120	300
Lymphoma, Peripheral T-Cell Non-Hodgkin	II	15	51
Lymphoma; Multiple Myeloma	I	6	36
Melanoma	I	1	28
Melanoma	I	3	31
Melanoma	I	10	50
Melanoma	I/II	10	146
Melanoma	Pivotal	23	1,694
Melanoma or Breast	III	8	163
Merkle Cell Carcinoma	I	1	10
Multiple Myeloma (MM)	EAP	70	1,915
Multiple Myeloma (MM)	I	5	60
Multiple Myeloma (MM)	I	11	240
Multiple Myeloma (MM)	I/II	3	45
Multiple Myeloma (MM)	I/II	20	158
Multiple Myeloma (MM)	II	4	50
Multiple Myeloma (MM)	II	10	40
Multiple Myeloma (MM)	II	30	159
Multiple Myeloma (MM)	II	50	174
Multiple Myeloma (MM)	III	40	300
Multiple Myeloma (MM)	III	250	502
Multiple Myeloma (MM); Lymphoma	I	6	40
Multiple Myeloma (MM); Lymphoma	I	7	65



Therapeutic Area / Indication	Study Phase	Sites	Patients
Myelodysplastic Syndrome (MDS)	EAP	20	480
Myelodysplastic Syndrome (MDS)	Ib/IIa	7	21
Myelodysplastic Syndrome (MDS)	II	3	30
Myelodysplastic Syndrome (MDS)	II	49	150
Myelodysplastic Syndrome (MDS)	II	60	176
Myelodysplastic Syndrome (MDS)	IIb	29	72
Myelodysplastic Syndrome (MDS)	IIb	29	72
Myelodysplastic Syndrome (MDS)	IV/Post-Marketing	6	80
Myelodysplastic Syndrome; Leukemia, Acute Myelogenous	I	20	87
Myelodysplastic Syndrome; Leukemia, Acute Myelogenous; Lymphoma; Multiple Myeloma; Chronic Myelomonocytic	I/II	9	60
Myelodysplastic Syndrome; Leukemia, Chronic Myelomonocytic	II	64	158
Myelofibrosis	I	3	60
Nasopharyngeal Carcinoma (NPC)	III	10	200
Ob/Gyn: Benign Prostatic Hyperplasia	Pilot/Feasibility	20	21
Ovarian	I	5	15
Ovarian	I/II	6	60
Ovarian	II	25	150
Ovarian	II	30	150
Ovarian; Pancreatic; Mesothelioma	I	20	1
Ovarian; Solid Tumors	I/Ib	6	66
Pancreatic	I	5	50
Pancreatic	I/II	6	43
Pancreatic	I/II	6	50
Pancreatic	I/II	25	186
Pancreatic	II	1	16
Pancreatic	II	12	49
Pigmented Villonodular Synovitis & Giant Cell Tumor of the Tendon Sheath	III	40	120

Therapeutic Area / Indication	Study Phase	Sites	Patients
Prostate	I	1	24
Prostate	I/II	6	36
Prostate	I/II	12	141
Prostate	I/II	17	120
Prostate	Ib	1	52
Prostate	Ib	6	111
Prostate	II	4	30
Prostate	II	5	50
Prostate	II	6	40
Prostate	II	8	40
Prostate	II	10	28
Prostate	II	15	50
Prostate	II	15	71
Prostate	II	40	110
Prostate	II	60	396
Prostate	II	65	450
Prostate	III	8	12
Prostate	III	70	292
Prostate	III	70	412
Prostate	III	107	150
Prostate	III	142	1,023
Prostate	III	150	1,200
Prostate	III	151	1,000
Prostate	III	160	1,860
Prostate	III	173	1,158
Prostate	III	305	1,500
Prostate	IV/Post-Marketing	70	500
Prostate Device	Pivotal	5	67
Renal Cell Carcinoma (RCC)	I	6	60
Renal Cell Carcinoma (RCC)	III	13	126
Renal Cell Carcinoma (RCC)	III	36	39
Renal Cell Carcinoma; Non-Hodgkin Lymphoma	I	7	26



Therapeutic Area / Indication	Study Phase	Sites	Patients
Soft Tissue Sarcoma	II	32	111
Soft Tissue Sarcoma	II	35	160
Soft Tissue Sarcoma; Ovarian; Lung; Breast	Pre-Clinical / Pre-IND	10	225
Solid Tumors	I	1	6
Solid Tumors	I	1	21
Solid Tumors	I	1	30
Solid Tumors	I	1	40
Solid Tumors	I	1	45
Solid Tumors	I	1	46
Solid Tumors	I	1	50
Solid Tumors	I	1	87
Solid Tumors	I	2	20
Solid Tumors	I	2	30
Solid Tumors	I	2	40
Solid Tumors	I	2	45
Solid Tumors	I	2	60
Solid Tumors	I	3	18
Solid Tumors	I	3	25
Solid Tumors	I	3	29
Solid Tumors	I	3	36
Solid Tumors	I	3	60
Solid Tumors	I	3	87
Solid Tumors	I	4	11
Solid Tumors	I	4	24
Solid Tumors	I	4	28
Solid Tumors	I	4	30
Solid Tumors	I	4	33
Solid Tumors	I	4	60
Solid Tumors	I	5	30
Solid Tumors	I	5	45
Solid Tumors	I	5	60
Solid Tumors	I	5	78
Solid Tumors	I	6	24
Solid Tumors	I	6	28

Therapeutic Area / Indication	Study Phase	Sites	Patients
Solid Tumors	I	7	40
Solid Tumors	I	7	71
Solid Tumors	I	7	85
Solid Tumors	I	9	21
Solid Tumors	I	9	75
Solid Tumors	I	11	56
Solid Tumors	I	15	65
Solid Tumors	I	17	48
Solid Tumors	I	47	42
Solid Tumors	I/Ib	13	107
Solid Tumors	I/II	1	24
Solid Tumors	I/II	4	24
Solid Tumors	I/II	5	40
Solid Tumors	I/II	10	88
Solid Tumors	Ib	5	70
Solid Tumors; Breast; Gastric	I	6	40
Solid Tumors; Colorectal; Squamous Cell Carcinoma of the Head & Neck	I/II	45	180
Solid Tumors; Intrahepatic Cholangiocarcinoma; Chondrosarcoma; Glioma	I/II	15	50
Solid Tumors; Lung, Non-Small Cell; Squamous Cell Carcinoma of the Head & Neck	I/II	40	198
Solid Tumors; Neuroendocrine Carcinoma (NEC); Neuroendocrine Prostate (NEPC)	I/II	12	288
Supportive Care, Anorexia, Cachexia	IV/Post-Marketing	3	50
Supportive Care, Antiemetic Therapy	II	15	90
Supportive Care, Hyperuricemia / Tumor Lysis Syndrome	II	21	170
Supportive Care, Hyperuricemia / Tumor Lysis Syndrome	II	25	276
Supportive Care, Hyperuricemia / Tumor Lysis Syndrome	Registry	6	30
Supportive Care, Oropharyngeal Candidiasis	III	13	189
Supportive Care, Thrombocytopenia	IIb	28	110
Thyroid Carcinoma, Anaplastic	II	3	30
Thyroid Carcinoma, Anaplastic	II/III	45	180